Mepolizumab

Mepolizumab

Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	IL-5
Clinical data
ATC code	L04AC06 (WHO)
Pharmacokinetic data
Elimination half-life	20 days
Identifiers
CAS Number	196078-29-2 N
ChemSpider	NA Y
KEGG	D04923 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
NY (what is this?)  (verify)

WikiDoc Resources for Mepolizumab
Articles
Most recent articles on Mepolizumab Most cited articles on Mepolizumab Review articles on Mepolizumab Articles on Mepolizumab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mepolizumab Images of Mepolizumab Photos of Mepolizumab Podcasts & MP3s on Mepolizumab Videos on Mepolizumab
Evidence Based Medicine
Cochrane Collaboration on Mepolizumab Bandolier on Mepolizumab TRIP on Mepolizumab
Clinical Trials
Ongoing Trials on Mepolizumab at Clinical Trials.gov Trial results on Mepolizumab Clinical Trials on Mepolizumab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mepolizumab NICE Guidance on Mepolizumab NHS PRODIGY Guidance FDA on Mepolizumab CDC on Mepolizumab
Books
Books on Mepolizumab
News
Mepolizumab in the news Be alerted to news on Mepolizumab News trends on Mepolizumab
Commentary
Blogs on Mepolizumab
Definitions
Definitions of Mepolizumab
Patient Resources / Community
Patient resources on Mepolizumab Discussion groups on Mepolizumab Patient Handouts on Mepolizumab Directions to Hospitals Treating Mepolizumab Risk calculators and risk factors for Mepolizumab
Healthcare Provider Resources
Symptoms of Mepolizumab Causes & Risk Factors for Mepolizumab Diagnostic studies for Mepolizumab Treatment of Mepolizumab
Continuing Medical Education (CME)
CME Programs on Mepolizumab
International
Mepolizumab en Espanol Mepolizumab en Francais
Business
Mepolizumab in the Marketplace Patents on Mepolizumab
Experimental / Informatics
List of terms related to Mepolizumab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mepolizumab is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5). Mepolizumab has been investigated or is under investigation for the treatment of severe eosinophilic asthma, atopic dermatitis, hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE), nasal polyposis, eosinophilic granulomatosis with polyangiitis (EGPA) (i.e., Churg Strauss syndrome), and chronic obstructive pulmonary disease (COPD). Phase III clinical trials in severe eosinophilic asthma were completed in 2014.